Asia s Biggest Pharma Hub At Baddi Plunges Into Crisis As Raw Material Prices Shoot Up
The main problem is the procurement of active pharmaceutical ingredients, a key manufacturing material, 85% of which comes from China.
With cost of the raw material, active pharmaceutical ingredients (API), having shot up sharply almost three to four-fold, the pharma companies are in dire straits. (Representtaional image.) Ashwani Sharma 2021-04-30T21:13:35+05:30 Asia s Biggest Pharma Hub At Baddi Plunges Into Crisis As Raw Material Prices Shoot Up outlookindia.com 2021-04-30T21:21:31+05:30
Also read
Asia’s biggest pharmaceutical hub, Baddi-Barotiwala-Nalagarh (BBN), producing several primary life-saving, anti-inflammatory, anti-viral, and Covid-19 drugs, is in a new crisis as the second Covid wave continues to batter India, bringing the already stretched healthcare system to its knees.